About Us
About Guard Therapeutics
Vision, Business Model & Goal
The Board
Management
Research
Kidney disease
Science
Pipeline
RMC-035
GTX Peptides
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Rights Issue 2025
Newsroom
Press releases
Event calender
Analyses and presentations
Subscribe
Contact
Swe
Search
Novel Therapies Targeting Kidney Disease
Latest Press Releases
Guard Therapeutics presents the Nomination Committee for 2026
(regulatory)
Read more
Guard Therapeutics appoints Redeye as financial advisor in the strategic review
Read more
Guard Therapeutics changes Certified Adviser to Redeye AB
(regulatory)
Read more
Press releases
16 Dec 2025 · Regulatory information
Guard Therapeutics presents the Nomination Committee for 2026
Read more
08 Dec 2025
Guard Therapeutics appoints Redeye as financial advisor in the strategic review
Read more
05 Dec 2025 · Regulatory information
Guard Therapeutics changes Certified Adviser to Redeye AB
Read more
04 Dec 2025 · Regulatory information
Guard Therapeutics Explores Strategic Alternatives
Read more
Show more
In focus
16 Sep 2025 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read more
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read more
Show more
Upcoming events
20 Feb 2026
Year-end report 2025
Read more
Show more
Event calendar
/
Financial calendar